Database→Orforglipron (Foundayo)

Tier 1Weight LossMetabolicDiabetesPREMIUM

Orforglipron (Foundayo)

Orforglipron (Foundayo / LY3502970), Oral Non-Peptide GLP-1 Receptor Agonist

FDA approved April 1, 2026 (Foundayo) for chronic weight management. Fastest NME approval since 2002 under Commissioner's National Priority Voucher Program. T2D submission anticipated 2026. Submitted in 40+ countries. Not a peptide: oral small molecule.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

Orforglipron (Foundayo) is the first non-peptide, oral small-molecule GLP-1 receptor agonist approved for weight management. FDA approved April 1, 2026. A once-daily pill taken without food or water restrictions. ATTAIN-1 (n=1,686, 72 weeks): 12.4% weight loss at highest dose. ATTAIN-2 (n=1,078, T2D): 10.5% weight loss, 1.8% HbA1c reduction. Superior to oral semaglutide on HbA1c in head-to-head ACHIEVE-3. ATTAIN-MAINTAIN: maintained weight loss in patients switching from injectable Wegovy/Zepbound. Less potent than injectable GLP-1s but eliminates injection and fasting barriers. Self-pay $149/month; $25/month with insurance.

🔒

Full Profile: Premium Members Only

The complete Orforglipron (Foundayo) profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use